Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.45 7.30 7.60 7.45 7.45 7.45 15,000 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 10

Evgen Pharma Share Discussion Threads

Showing 1751 to 1775 of 1850 messages
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
DateSubjectAuthorDiscuss
11/11/2019
08:30
Who's great Idea was it to release primary & secondary endpoint data together? They led us up the garden path there!
90005nelson
11/11/2019
08:25
Did not expect that - unmitigated failure. Wow. I thought there would be at least some plus points ...none.
pennyfalls
11/11/2019
08:25
Little available -
tomboyb
11/11/2019
08:17
Well it's NT to buy
babbler
11/11/2019
08:08
Yes the drug does work in breast cancer as you have proved! The current market cap of £7 million is madness bearing that in mind.
nobbygnome
11/11/2019
08:01
I think those that have sold will regret it
dave444
11/11/2019
07:59
Remember everyone I’m still on this drug and will be at least till next scan in December....there217;s always a positive 😀😀
blakeysangel
11/11/2019
07:58
It will be good to buy at
dave444
11/11/2019
07:57
Must be abig seller at that price gor them to lower it
letmepass
11/11/2019
07:53
Someone keen to push this down by the tick down
dave444
11/11/2019
07:44
Crazy overreaction
dave444
11/11/2019
07:43
A ridiculous mark down in the price pre market. There is no way the SAH indication was worth that proportion of the market cap. Those nasty MMs are taking no chances...
nobbygnome
11/11/2019
07:27
Good call Nobby; I wish my gut feeling had been more aligned with yours! Oh well, as you state, hopefully good news will arise elsewhere with the breast cancer trial. Not topping up, but not selling yet either (probably will not be worth it anyway at this stage).
lovewinshatelosses
11/11/2019
07:22
The Breast cancer result were good so commercialization should come off the back of that!
dave444
11/11/2019
07:20
Sub 10p coming.
letmepass
11/11/2019
07:17
Very disappointing for investors but more importantly stroke sufferers.
pdt
11/11/2019
07:05
Oh dear. Hopefully it won't go down too much because at least sulforaphane has been shown to work in the breast cancer trial. Obviously I am relieved I didn't buy in on the back of this trial result but commiserations to those who did. The thrills and spills of biotech investment....
nobbygnome
10/11/2019
18:56
Big week coming up, we're well into Q4 now.
90005nelson
08/11/2019
19:25
I could have waited and got a few more but news could trip anytime!
dave444
07/11/2019
13:09
That was a very enjoyable post, offering some good recap material - and look, I am long here and cautiously optimistic, so really would be delighted if we see those levels in the short term. I guess I have just seen too many broker targets that have never got close to being accurate in the end, especially with small caps. I have no intention of selling before news on both fronts however and if good, will look to ride it out for some time afterwards, maybe all the way to the end game.
lovewinshatelosses
07/11/2019
11:05
The Finncap quote innSerial investor post about 4 posts ago quotes 35p after breast cancer March results 81p on a successful result in SAH this month It also says a first loyalty payment between $50-$100m Q1 2020.If those come in this will be over £1
dave444
07/11/2019
10:56
The trades today are all showing as sells (whether that is true or not though of course, who knows); no movement currently in the share price A buyer in the background mopping up the sells with ease I wonder? Anyway, where do you get your £1 - £1.50 figure from dave? I would be delighted if you were right, but it seems a bit optimistic! :)
lovewinshatelosses
06/11/2019
20:39
£1/share is the minimum this will be at post deal!Probably more realistically £1.50/share!So selling out at 16.50p is not very bright!!!!!
dave444
04/11/2019
10:49
Excellent post!I am locked and loaded
dave444
04/11/2019
06:43
Private investors would be wise to take note: • March 25 2019: Stunningly positive headline results from the Phase II trial of SFX-01 in metastatic breast cancer. SFX-01 is shown to halt the growth of tumours, and in some cases to significantly shrink the tumours, with minimal side effects; something rarely seen in the field of oncology. • April 02 2019: House broker FinnCap initiates research on the company with an initial target price of 35p but indicates that any further positive readouts (relating to ongoing trials with SFX-01) should demand prices in excess of 85p. • April 17 2019: The company raises £5m (at 15p) in a heavily oversubscribed placing and advises the market that out-licensing discussions (with pharma majors) are underway with the potential for substantial value enhancement for shareholders. • April 23 2019: Millionaire venture investor, chess maestro, and former CEO of Silence Therapeutics, Ali Mortazavi, snaps-up 3.3m placing shares (3% of the company). • April 24 2019: Millionaire serial investor, and head honcho of Ora Capital, Richard Griffiths, snaps-up 3.4m placing shares to take his holding to 7.3m (6% of the company). • May 22 2019: Millionaire serial investor, and head honcho of Ora Capital, Richard Griffiths snaps-up a further 3m shares to take his holding to 10.3m (7.5% of the company). • August 05 2019: Agreement signed with King's College London and the British Heart Foundation to see if SFX-01 can provide neurovascular protection in both stroke and potentially wider neuropsychiatric complications.' • August 07 2019: European Patent Office grants further intellectual property rights in Europe pertaining to its proprietary technology, Sulforadex (the novel composition of SFX-01). Patents have already been granted in the USA and other territories. • September 05 2019: Memorandum of Understanding penned with Guy's and St Thomas' NHS Foundation Trust to supply SFX-01 to support a clinical trial in patients diagnosed with Autism Spectrum Disorder (ASD). There are currently no approved medicines for treating the three core symptoms of autism (communication difficulties, social challenges and repetitive behaviour) which have long represented a huge area of unmet clinical need for affected families. Based on its novel mode-of-action, SFX-01 has the potential to become a first-in-class treatment for the core symptoms of ASD, disrupting the current £3bn ASD market. • November 2019: Top line results for the Phase II trial of SFX-01 (after subarachnoid haemorrhage) are expected to be announced. There’s heightened confidence amongst investors and the medical fraternity that the results will meet the primary endpoints of safety, tolerability, and blood flow, along with key secondary endpoints measuring cognition, MRI and biomarkers. According to the Lancet, there’s been no new drugs for treating subarachnoid haemorrhage (SAH), for 28½ years and so a positive readout would be materially significant for the pharmaceutical industry and highly transformational for the company. • Evgen Pharma’s cash position at 31 March 2019 was £2.0m. However, the company went on to raise £5m at the backend of April 2019 thereby taking its cash position to £7.5m (inclusive of a £0.5m tax credit). And assuming five months’ worth of routine clinical expenditure and recurring administrative costs, the company’s cash position at November 05 2019 is projected to stand at circa £6.9m. ............................................................................................... So, with a market cap of £21m (16.5p), and less £6.9m of cash and cash equivalents, means the market is valuing SFX-01 at a paltry £14.1m. And that doesn’t even factor-in the potential value uplift that may come about from the ongoing out-licensing discussions or from a positive readout of the company’s Phase II trial of SFX-01 – expected imminently. Remember, the company has been granted orphan drug designation by the FDA for SFX-01 (in the treatment of subarachnoid haemorrhage). Orphan drug designation gives SFX-01 US market exclusivity for seven years from the date of marketing approval. Thus, should the November readout prove to be successful, the FDA are on course to approve SFX-01 thereby providing a quick route to market and allowing significant revenues to be generated whilst a Phase 3 study is conducted. To that end, analysts are forecasting the first milestone payment (in early 2020) to be in the region of $50-$100 million. Two words: Significantly undervalued. Https://www.finncap.com/news-events/finncap-research-company-notes-18-april-2019 .
serialinvestor1
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191210 23:49:40